Erasca, Inc.

NasdaqGS:ERAS Stok Raporu

Piyasa değeri: US$6.0b

Erasca Yönetim

Yönetim kriter kontrolleri 3/4

Erasca CEO'su Jonathan Lim, Jul2018 tarihinde atandı, in görev süresi 7.75 yıldır. in toplam yıllık tazminatı $ 4.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.6% maaş ve 84.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 10.4% ine doğrudan sahiptir ve bu hisseler $ 620.58M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.2 yıl ve 7.8 yıldır.

Anahtar bilgiler

Jonathan Lim

İcra Kurulu Başkanı

US$4.3m

Toplam tazminat

CEO maaş yüzdesi15.59%
CEO görev süresi8yrs
CEO sahipliği10.4%
Yönetim ortalama görev süresi5.2yrs
Yönetim Kurulu ortalama görev süresi7.8yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • May 11

Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks

Summary I initiate Erasca (ERAS) with a "Hold" rating due to promising phase 1 ERAS-0015 data but significant risks. ERAS-0015 showed high ORR in KRAS-mutant NSCLC [64%] and PDAC [50%] at RDE but faces safety and patent litigation risks. Company has strong cash reserves, global rights to ERAS-0015, and a Merck supply collaboration agreement for combination trials. Upcoming 2027 data readouts for ERAS-0015 and resolution of safety or patent issues are key catalysts for ERAS. Read the full article on Seeking Alpha
Seeking Alpha • Apr 25

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Summary Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, naporafenib, shows preliminary efficacy in NRAS-mutant melanoma, with key phase 3 data expected in 2025. Financially stable with a cash runway into at least 2027, Erasca can advance its pipeline without immediate funding concerns, mitigating dilution risk. Despite market pessimism, signals of activity in their trials and potential in pan-RAS inhibitors justify a tentative "Buy" sentiment for long-term gains. Read the full article on Seeking Alpha
Seeking Alpha • Jan 27

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Summary Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. I see the company has a robust balance sheet, with roughly $463.3 million in cash and equivalents as of Q3, 2024. They estimate a runway into 2H2027. SEACRAFT-1 already showed that Naporafenib has potentially better efficacy compared to the SoC and competitors. I believe Naporafenib could have an FDA submission by late 2025 or 2026. Plus, ERAS has a nicely diversified pipeline for broader RAS cancers. So, given that the stock has already pulled back 40.7% from its 2024 highs, I think ERAS now looks compelling at these levels. Read the full article on Seeking Alpha
Seeking Alpha • Sep 30

Erasca: New Focus After Restructuring, But Need More Differentiation

Summary Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma, showing preliminary antitumor activity and manageable safety. Naporafenib, combined with trametinib, demonstrated better PFS and ORR compared to historical benchmarks, despite mixed efficacy and safety data from previous trials. Erasca's financials are solid with a market cap of $755mn and a cash balance of $460mn, providing 8-9 quarters of runway. Despite promising data, the target market's difficulty and Erasca's history of program abandonment warrant cautious observation from the sidelines. Read the full article on Seeking Alpha
Seeking Alpha • Oct 20

Erasca forms clinical trial partnership with Pfizer for cancer therapy

The clinical-stage biotech Erasca, Inc. (NASDAQ:ERAS) and Pfizer (PFE) announced an agreement on Thursday to jointly investigate a cancer therapy combining the former’s experimental therapy, ERAS-007, and PFE’s blockbuster breast cancer therapy Ibrance. As part of the clinical trial collaboration and supply agreement, the companies will test Ibrance, also known as Palbociclib, in combination with ERAS-007 in a proof-of-concept study for colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) with certain genetic mutations. The therapeutic combination is currently being studied in a Phase 1b/2 HERKULES-3 master protocol study for gastrointestinal (GI) malignancies, sponsored by ERAS with Palbociclib supplied from PFE at no cost.   ERAS-007 is an ERK1/2 inhibitor, and Ibrance is a CDK4/6 inhibitor. The latter added $5.4B to Pfizer’s (PFE) topline in 2021.
Seeking Alpha • Sep 07

Erasca adds 10% ahead of R&D Day

The shares of recently IPO’d clinical-stage biotech Erasca, Inc. (NASDAQ:ERAS) jumped ~10% in the morning hours Wednesday as the company prepares to hold an R&D Day with a focus on its lead candidates ERAS-007 and ERAS-601. Meanwhile, according to a regulatory filing submitted on Tuesday, PFM Health Sciences GP, LLC, a San Francisco-based firm with nearly $2B investments under management, had disclosed a ~6% stake in ERAS. At the R&D event, scheduled at 4:30 PM on Wednesday, KOL David S. Hong, M.D., of MD Anderson Cancer Center, will highlight the opportunities and current treatments for cancers driven by the RAS/MAPK pathway, where ERAS focuses. In addition, the company will share early clinical results for ERAS-007 and ERAS-601 in advanced solid tumors.
Seeking Alpha • Jul 18

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Erasca (NASDAQ:ERAS) on Monday said it had entered into a clinical trial collaboration and supply agreement with Eli Lilly (LLY) to support its ongoing phase 1/1b FLAGSHP-1 trial. ERAS stock +4.8% to $6.97 in premarket trading The early-stage trial will evaluate ERAS' inhibitor ERAS-601 in combination with Lilly's (LLY) antibody cetuximab for the treatment of a type of cancer of the colon and the skin called triple wildtype metastatic colorectal cancer and human papillomavirus-negative advanced head and neck squamous cell carcinoma, respectively. Erasca (ERAS) is the trial's sponsor, while LLY will supply cetuximab at no cost. ERAS had previously signed collaboration and supply agreements with LLY and Pfizer (PFE) to evaluate a combination of cetuximab and PFE's encorafenib with its inhibitor ERAS-007.

CEO Tazminat Analizi

Jonathan Lim'un ücretlendirmesi Erasca'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$277m

Dec 31 2025US$4mUS$670k

-US$125m

Sep 30 2025n/an/a

-US$128m

Jun 30 2025n/an/a

-US$128m

Mar 31 2025n/an/a

-US$158m

Dec 31 2024US$4mUS$645k

-US$162m

Sep 30 2024n/an/a

-US$159m

Jun 30 2024n/an/a

-US$158m

Mar 31 2024n/an/a

-US$127m

Dec 31 2023US$5mUS$623k

-US$125m

Sep 30 2023n/an/a

-US$231m

Jun 30 2023n/an/a

-US$236m

Mar 31 2023n/an/a

-US$240m

Dec 31 2022US$8mUS$593k

-US$243m

Sep 30 2022n/an/a

-US$138m

Jun 30 2022n/an/a

-US$149m

Mar 31 2022n/an/a

-US$141m

Dec 31 2021US$850kUS$498k

-US$123m

Sep 30 2021n/an/a

-US$154m

Jun 30 2021n/an/a

-US$119m

Mar 31 2021n/an/a

-US$96m

Dec 31 2020US$2mUS$300k

-US$102m

Tazminat ve Piyasa: Jonathan 'nin toplam tazminatı ($USD 4.30M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 8.35M ).

Tazminat ve Kazançlar: Jonathan şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jonathan Lim (54 yo)

8yrs
Görev süresi
US$4,298,838
Tazminat

Dr. Jonathan E. Lim, M.D., is Member of Advisory Board of Independa, Inc. Dr. Lim is Managing Partner and Founder of City Hill Ventures, LLC. Dr. Lim is Co-Founder, Chairman & CEO of Erasca, Inc. from Marc...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Jonathan Lim
Co-Founder8yrsUS$4.30m10.4%
$ 620.6m
David Chacko
CFO & Chief Business Officer5.6yrsUS$1.78m0.090%
$ 5.4m
Michael Varney
Chairman of Research & Development5.9yrsUS$215.09k0%
$ 0
Shannon Morris
Chief Medical Officer4.2yrsUS$1.75m0%
$ 0
Nik Chetwyn
Chief Operating Officer5.2yrsVeri yokVeri yok
Alison Milhous
Senior Vice President of Accountingless than a yearVeri yokVeri yok
Robert Shoemaker
Chief Scientific Officerless than a yearVeri yokVeri yok
Ebun Garner
Chief Legal Officer & Corporate Secretary5.3yrsUS$2.02m0.0081%
$ 480.8k
Lisa Tesvich-Bonora
Chief People Officer4.5yrsVeri yokVeri yok
Brian Baker
Senior Vice President of Finance5.2yrsVeri yokVeri yok
Chandra Lovejoy
Chief Regulatory Affairs Officer5.2yrsVeri yokVeri yok
Minli Xie
Senior Vice President of Pharmaceutical Development & Operations3.7yrsVeri yokVeri yok
5.2yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş

Deneyimli Yönetim: ERAS 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.2 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jonathan Lim
Co-Founder7.8yrsUS$4.30m10.4%
$ 620.6m
Michael Varney
Chairman of Research & Development5.9yrsUS$215.09k0%
$ 0
George Demetri
Scientific Advisory Board Memberno dataVeri yokVeri yok
Alexander Casdin
Independent Director8yrsUS$176.91k0.21%
$ 12.8m
Pratik Multani
Independent Director8yrsUS$166.91k0.056%
$ 3.3m
Kevan Shokat
Scientific Advisory Board Memberno dataVeri yokVeri yok
James Bristol
Lead Independent Director8.1yrsUS$208.91k0.067%
$ 4.0m
Julie Hambleton
Independent Director5.3yrsUS$175.41k0.0019%
$ 115.1k
Ryan Corcoran
Scientific Advisory Board Memberno dataVeri yokVeri yok
Valerie Harding-Start
Independent Director7.1yrsUS$177.91k0.0071%
$ 421.7k
Karen Cichowski
Scientific Advisory Board Memberno dataVeri yokVeri yok
Pablo Rodriguez-Viciana
Scientific Advisory Board Memberno dataVeri yokVeri yok
7.8yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: ERAS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/07/10 14:43
Gün Sonu Hisse Fiyatı2026/07/10 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Erasca, Inc. 14 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Alec StranahanBofA Global Research
Naureen QuibriaCapital One Securities, Inc.
Hiroshi ShibutaniGoldman Sachs